Use of glucagon-like peptide 1 receptor agonists and risk of serious renal events: Scandinavian cohort study
Karnwal A, Jassim AY, Mohammed AA, Sharma V, Al-Tawaha ARMS, Sivanesan I
In this post, were going to dive into: The biological "why": How these meds change the way your stomach empties
As liraglutide and semaglutide induced stronger HbA1c reductions versus placebo then lixisenatide, it was important that the authors showed in reply to a letter to the editor that the anti-albuminuric effects were independent of glucose-lowering in post-hoc analyses
Western blotting (WB) results show that the expression of apoptotic protein increased with the increased concentration of AP probe-net
Health Benefits and Risk Reductions Associated with GLP-1 Medications Health Benefits and Risk Reductions Associated with GLP-1 Medications Kidney and Liver Health Improvements The FLOW trial demonstrated 24% reduction in major kidney disease events among patients with type 2 diabetes and chronic kidney disease ^39
